154 related articles for article (PubMed ID: 25054070)
1. Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer.
Muqeet Adnan M; Bhutta U; Iqbal T; AbdulMujeeb S; Haragsim L; Amer S
Case Rep Nephrol; 2014; 2014():565393. PubMed ID: 25054070
[TBL] [Abstract][Full Text] [Related]
2. Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer.
Patell K; Ajay K; Al Armashi AR; Bawwab A; Ravakhah K
J Oncol Pharm Pract; 2022 Apr; 28(3):698-702. PubMed ID: 34693819
[TBL] [Abstract][Full Text] [Related]
3. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
4. Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.
Watthanasuntorn K; Abid H; Gnanajothy R
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567243
[TBL] [Abstract][Full Text] [Related]
5. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
Uhm SJ; Hall JA; Herrington JD
J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
[TBL] [Abstract][Full Text] [Related]
6. SEVERE, PROLONGED, DENOSUMAB-INDUCED HYPOCALCEMIA WITH RECOVERY AFTER 111 DAYS OF HIGH-DOSE CALCIUM SUPPLEMENTATION.
McCaleb RV; Johnson JT
AACE Clin Case Rep; 2019; 5(1):e82-e85. PubMed ID: 31967007
[TBL] [Abstract][Full Text] [Related]
7. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
Lau LH; Cliff ERS; Wong V; Wong H; Torkamani N; Eer A; Weickhardt A; Grossmann M
Clin Endocrinol (Oxf); 2020 Jun; 92(6):495-502. PubMed ID: 32017154
[TBL] [Abstract][Full Text] [Related]
8. Hypocalcemia in a Patient With Metastatic Prostate Cancer From Denosumab Treatment.
Gouli S; Wang J; Patel A; Allerton J
Cureus; 2021 Aug; 13(8):e17046. PubMed ID: 34522524
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
Watkins KR; Rogers JE; Atkinson B
Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
[TBL] [Abstract][Full Text] [Related]
10. A Case of Recurrent Severe Hypocalcemia with Prolonged Hospitalization and Readmissions After Single Dose of Denosumab in Metastatic Prostate Cancer Patient.
Kc O; Dahal PH; Koirala M; Kothagundla CS; Al Zaghal E; Fahed R
J Community Hosp Intern Med Perspect; 2022; 12(2):60-64. PubMed ID: 35712685
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Denosumab-Induced Hypocalcemia and Hypophosphatemia in the Setting of Metastatic Prostate Cancer.
Flood MG; Rowley MA; Basnet A
Cureus; 2022 Jan; 14(1):e20928. PubMed ID: 35145817
[TBL] [Abstract][Full Text] [Related]
12. Denosumab causing severe, refractory hypocalcaemia in a patient with chronic kidney disease.
Saleem S; Patel S; Ahmed A; Saleem N
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29848528
[TBL] [Abstract][Full Text] [Related]
13. Denosumab-Induced Hypocalcemia after Billroth II Gastric Bypass Surgery.
Schmucker AM; Green DE; Montemuro PM
Case Rep Endocrinol; 2020; 2020():8833723. PubMed ID: 32774945
[TBL] [Abstract][Full Text] [Related]
14. Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer.
Gunawan F; George E; Kotowicz M
Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829971
[TBL] [Abstract][Full Text] [Related]
15. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
16. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
17. Sustained hypophosphatemia after denosumab in a patient on hemodialysis.
Almodares AAS; Elder GJ; Abrahamsen B
Bone; 2024 Apr; 181():117045. PubMed ID: 38341165
[TBL] [Abstract][Full Text] [Related]
18. Hypocalcemia in Patients With Osteoporosis and Normal Renal Function, Treated With Denosumab, a Retrospective Analysis.
Bitar ZI; Hajjiah AM; Maadarani OS; Elzoueiry MM; Gohar MR; Abdelfatah M; Alabdali F
Nutr Metab Insights; 2024; 17():11786388231223604. PubMed ID: 38205220
[TBL] [Abstract][Full Text] [Related]
19. [Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation].
Saito Y; Uchiyama K; Sakamoto T; Yamazaki K; Kubota K; Takekuma Y; Komatsu Y; Sugawara M
Yakugaku Zasshi; 2021; 141(8):1023-1030. PubMed ID: 34334547
[TBL] [Abstract][Full Text] [Related]
20. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
Yasuda Y; Iwama S; Arima H
Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
